Medipharm Labs (Otc) (TSE:LABS) has released an update.
MediPharm Labs, a pharmaceutical company specializing in cannabinoids, has reported a positive outlook on its German operations following Germany’s decision to decriminalize personal cannabis use and cultivation, effective April 1, 2024. The legislative change, which also deregulates medical cannabis, is expected to broaden patient access and reduce stigma, potentially benefiting MediPharm’s German subsidiary, Beacon Medical, and its partnership with STADA. MediPharm’s expansion in Germany includes increased product approvals and a new THC isolate supply business, supported by its GMP-certified manufacturing sites in Ontario.
For further insights into TSE:LABS stock, check out TipRanks’ Stock Analysis page.
